Semiquantitative RT-PCR evaluation of the MDR1 gene expression in patients with acute myeloid leukemia

Neoplasma

Volumn 54, Issue 5, 2007, Pages 383-390

  Trnkova Z ^a   Bedrlikova R ^a   Markova J ^a   Michalova K ^a   Stockbauer P ^a   Schwarz, J ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

AML; Cytogenetics; MDR1 gene; Prognosis; Semiquantitative RT PCR

Indexed keywords

CORE BINDING FACTOR BETA; MULTIDRUG RESISTANCE PROTEIN 1; MYOSIN HEAVY CHAIN; MYOSIN HEAVY CHAIN 11; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID RECEPTOR ALPHA; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; BREAKPOINT CLUSTER REGION PROTEIN; GLYCOPROTEIN P; PRIMER DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE MARROW; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FEMALE; FUSION GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; ACUTE DISEASE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; MORTALITY; MYELOID LEUKEMIA; SURVIVAL;

ACUTE DISEASE; DNA PRIMERS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS C-BCR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 35448955738     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. BAUDARD M, BEAUCHAMP-NICOUD A, DELMER A, et al. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia 1999; 13: 1481-1490.
2. MCKENNA SL, PADUA RA. Multidrug resistance in leukaemia. Br J Haematol 1997; 96: 659-674.
3. BOSCH I, CROOP J. P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1996; 1288: F37-54.
4. MARIE JP, ZHOU DC, GURBUXANI S, et al. MDR1/Pglycoprotein in haematological neoplasms. Eur J Cancer 1996; 32A: 1034-1038.
5. JURANKA PF, ZASTAWNY RL, LING V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 1989; 3: 2583-2592.
6. SHAPIRO AB, LING V. The mechanism of ATP-dependent multidrug transport by P-glycoprotein. Acta Physiol Scand Suppl 1998; 643: 227-234.
7. GALIMBERTI S, GUERRINI F, PALUMBO GA, et al. Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leuk Res 2004; 28: 367-372.
8. HOMOLYA L, HOLLÓ M, MÜLLER M, et al. A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells. Br J Cancer 1996; 73: 849-855.
9. LEITH CP, KOPECKY KJ, GODWIN J, MCCONNELL T, SLOVAK ML et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323-3329.
10. LIST AF. Multidrug resistance: clinical relevance in acute leukemia. Oncology (Williston Park) 1993; 7: 23-28.
11. SCHAICH M, SOUCEK S, THIEDE C, et al. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 2005; 128: 324-332.
12. VAN DEN HEUVEL-EIBRINK MM, VAN DER HOLT B, TE BOEKHORST PA, et al. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br J Haematol 1997; 99: 76-83.
13. BÜCHNER T, HIDDEMANN W, BERDEL W, et al. Acute myeloid leukemia: treatment over 60. Rev Clin Exp Hematol 2002; 6: 46-59.
14. PINTO A, ZAGONEL V, FERRARA F. Acute myeloid leukemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol 2001; 39: 275-287.
15. GARRIDO SM, COOPER JJ, APPELBAUM FR, et al. Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. Leuk Res 2001; 25: 23-32.
16. WUCHTER C, LEONID K, RUPPERT V, et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000; 85: 711-721.
17. LEITH CP, KOPECKY KJ, CHEN IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood 1999; 94: 1086-1099.
18. LOHRI A, VAN HILLE B, BACCHI M, et al. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDRassociated protein, glutathione-S- transferase, bcl-2 and topoisomerase IIα) in 57 newly diagnosed acute myeloid leukaemias. Eur J Haematol 1997; 59: 206-215.
19. MARIE JP, HUET S, FAUSSAT AM, et al. Multicentric evaluation of the MDR phenotype in leukemia. Leukemia 1997; 11: 1086-1094.
20. - cases. Blood 1995; 86: 2329-2342.
21. MARIE JP, LEGRAND O, PERROT JY, et al. Measuring multidrug resistance expression in human malignancies: elaboration of consensus recommendations. Semin Hematol 1997; 34: 63-71.
22. DRACH D, ZHAO S, DRACH J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992; 80: 2729-2734.
23. SUÁREZ L, VIDRIALES B, GARCÍA-LARAÑA J, et al. Multiparametric analysis of apoptotic and multidrug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia. Haematologica 2001; 86: 1287-1295.
24. VAN STIJN A, VAN DER POL MA, KOK A, et al. Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica 2003; 88: 497-508.
25. BASSO G, LANZA F, ORFAO A, et al. Clinical and biological significance of CD34 expression in acute leukemia. J Biol Regul Homeost Agents 2001; 15: 68-78.
26. LEGRAND O, ZOMPI S, PERROT JY, et al. P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetics risk groups. Haematologica 2004; 89: 34-41.
27. PAIETTA E, ANDERSEN J, RACEVSKIS J, et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia 1994; 8: 968-973.
28. DRACH D, ZHAO S, DRACH J, ANDREEFF M. Low incidence of MDR1 expression in acute promyelocytic leukaemia. Br J Haematol 1995; 90: 369-374
29. DELAUNAY J, VEY N, LEBLANC T, et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood 2003; 102: 462-469.
30. NGUYEN S, LEBLANC T, FENAUX P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood 2002; 99: 3517-3523.
31. SUVANNASANKHA A, MINDERMAN H, O'LOUGHLIN KL, et al.. Expression of the neural cell adhesion molecule CD56 is not associated with P-glycoprotein overexpression in core-binding factor acute myeloid leukemia. Leuk Res 2004; 28: 449-455.
32. VARDIMAN JW, HARRIS NL, BRUNNING RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
33. BENNETT JM, CATOVSKY D, DANIEL MT, et al. Proposals for the classification of the acute leukaemias. Br J Haematol 1976; 33: 451-458.
34. CHOMCZYNSKI P, SACCHI N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
35. LOHRI A, VAN HILLE B, REUTER J, et al. mRNA expression, measured by quantitative reverse transcriptase polymerase chain reaction, of five putative drug resistance parameters, in normal and leukaemic peripheral blood and bone marrow. Acta Haematol 1997; 98: 1-7.
36. WATZINGER F, LION T. Multiplex PCR for quality control of template RNA/cDNA in RT-PCR assays. Leukemia 1998; 12: 1984-1993.
37. PIZZONIA J. Electrophoresis gel image processing and analysis using the KODAK 1D software. Biotechniques 2001; 30: 1316-1320.
38. BIONDI A, RAMBALDI A, PANDOLFI PP, et al. Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992; 80: 492-497.
39. SMETSERS TF, STEVENS EH, VAN DE LOCHT LT, et al. Freezing of PCR master mixture retains full amplification activity and facilitates PCR standardisation for molecular diagnostics and real-time quantitative PCR. Leukemia 1998; 12: 1324-1325.
40. CLAXTON DF, LIU P, HSU HB, et al. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood 1994; 83: 1750-1756.
41. GRIMWADE D, WALKER H, OLIVER F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322-2333.
42. MRÓZEK K, BALDUS CD, MARCUCCI G, et al. Acute myeloid leukemia prognostic factors: from cytogenetics to chip. Hematology (Eur Hematol Assn Educ Progr) 2005; 1: 116-122.
43. GALIMBERTI S, GUERRINI F, CARULLI G, et al. Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis. Eur J Haematol 2004; 72: 45-51.
44. TRNKOVÁ Z, PEKOVÁ S, BEDRLÍKOVÁ R, et al. Type J CBFβ/MYH11 transcript in the M4eo subtype of acute myeloid leukemia. Hematology 2003, 8: 115-117.
45. TAKESHITA A, SHINJO K, OHNISHI K, OHNO R. Expression of multidrug resistance P-glycoprotein in myeloid progenitor cells of different phenotype: comparison between normal bone marrow and cells and leukaemia cells. Br J Haematol 1996; 93: 18-21.
46. GRUBER A, ARESTRÖM I, ALBERTIONI F, et al. Multidrug resistance (Mdr1) gene expression in peripheral blasts from patients with acute leukemia only rarely increases during disease progression after combination chemotherapy. Leuk Lymphoma 1995; 18: 435-442.